Results 51 to 60 of about 720,196 (232)

Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score–Weighted Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin cardiac amyloidosis results from the deposition of misfolded amyloid fibrils in cardiac tissue, leading to progressive heart failure.
Louise Zmuda, Amira Zaroui, Mounira Kharoubi, Emmanuelle Boutin, Frédéric Roca, Silvia Oghina, Emmanuel Teiger, Marie Laurent, Florence Canoui‐Poitrine, Thibaud Damy, Amaury Broussier   +10 more
doaj   +1 more source

Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study

ESC Heart Failure
Aims Predicting mortality in severe AL cardiac amyloidosis is challenging due to elevated biomarker levels and limited thresholds for stratifying severe cardiac damage.
Amira Zaroui, Mounira Kharoubi, Romain Gounot, Silvia Oghina, Charlotte Degoutte, Melanie Bezard, Arnault Galat, Soulef Guendouz, Louise Roulin, Vincent Audard, Vincent Leroy, Emmanuel Teiger, Elsa Poullot, Valérie Molinier‐Frenkel, Fabien Le Bras, Karim Belhadj, Jean‐Philippe Bastard, Soraya Fellahi, Jason Shourick, Francois Lemonier, Thibaud Damy   +20 more
doaj   +1 more source

Cardiac amyloidosis in a kidney transplant recipient [PDF]

Journal of Nephropathology
Systemic amyloidosis is a collection of diseases caused by the deposition of protein fibrils in organ tissues, leading to significant morbidity. Cardiac amyloidosis, a rare and debilitating condition, can affect any organ in the body.
Bahareh Marghoob, Mohammad Hassan Fallahkohan   +1 more
doaj   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

The great mimicker: Multimodality imaging in cardiac sarcoidosis

Romanian Journal of Cardiology
Cardiac sarcoidosis is a granulomatous inflammatory disease that can mimic genetic cardiomyopathies, making diagnosis challenging, particularly in young patients with preserved ventricular function.
Neculae Gabriela, Chadhaa Gagan Deep Singh, Hentati Mouna, Oghina Silvia, Damy Thibaud   +4 more
doaj   +1 more source

DNA Nanotechnology Meets Peptide and Protein Self‐Assembly

Chemistry – A European Journal, EarlyView.
Combining DNA nanotechnology with peptide and protein assembly provides complementary platforms for the rational engineering of functional biomaterials. This Perspective discusses the emerging field of self‐assembling DNA‐peptide and DNA‐protein hybrid systems that combine the structural precision and programmability of DNA nanotechnology with the ...
Marcel Hanke, Nanjundan Raghul, Adrian Keller, Veikko Linko, Verónica I. Dodero   +4 more
wiley   +1 more source

Systemic Amyloidosis – Insights by Cardiovascular Magnetic Resonance [PDF]

, 2015
Systemic amyloidosis is the exemplar infiltrative, extracellular disease. Although it is a multi-organ disorder, cardiac involvement drives prognosis. Survival is worst in the AL amyloidosis subtype. It can affect any age and any race. There is no direct
Banypersad, SM
core  

Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis

ESC Heart Failure, Volume 12, Issue 2, Page 809-818, April 2025.
Abstract Aims This study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light‐chain amyloidosis (AL) and hereditary (ATTRv) and wild‐type transthyretin amyloidosis (ATTRwt)].
Alessia Argirò, Mattia Zampieri, Carlotta Mazzoni, Carlo Fumagalli, Michela Baccini, Alessandra Mattei, Alberto Cipriani, Laura De Michieli, Aldostefano Porcari, Gianfranco Sinagra, Marco Merlo, Giacomo Tini, Beatrice Musumeci, Domitilla Russo, Pier Filippo Vianello, Marco Canepa, Roberto Licordari, Gianluca di Bella, Claudio Rapezzi, Federico Perfetto, Francesco Cappelli   +20 more
wiley   +1 more source

Misdiagnosis of hereditary amyloidosis as AL (Primary) amyloidosis [PDF]

, 2002
Background: Hereditary, autosomal dominant amyloidosis, caused by mutations in the genes encoding transthyretin, fibrinogen A -chain, lysozyme, or apolipoprotein A-I, is thought to be extremely rare and is not routinely included in the differential ...
Booth, D.R., Gilbertson, J.A., Hawkins, P.N., Booth, S.E., Lachmann, H.J., Gillmore, J.D., Bybee, A., Pepys, M.B.   +7 more
core  

Heart transplantation in cardiac amyloidosis

, 2022
It is known that the prognosis of patients affected by light-chain (AL) or transthyretin-related (TTR) amyloidosis is poor. TTR amyloidosis has usually shown a slower progression than AL amyloidosis, both hereditary TTR amyloidosis, where there is an ...
Giorgio Guzzi, Driussi M., Giovanni Benedetti, Igor Vendramin, Ugolino Livi, Chiara Nalli, Vendramin I., Guzzi G., Nalli C., Sponga S., Imazio M., Sandro Sponga, Massimo Imazio, Di Nora C., Benedetti G., Livi U., Mauro Driussi, Concetta Di Nora   +17 more
core   +2 more sources